ClinicalTrials.gg

Program

FXR0906

A development code. Also written as “FXR0906 injection”, “Intervention1: FXR0906 injection” and “Intervention2: FXR0906 injection”.

In Fosun Pharma's pipeline, ApoC3 siRNA. Its studies are led by Fosun Pharma.

Furthest: phase 2, since Oct 13, 20262 company-led studies, 2 open or runningNext primary completion: Sep 24, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma22 open or runningphase 2since Oct 13, 2026Jul 27, 2026Sep 24, 2027phase 1 · NCT07766759
  • Named in Fosun Pharma’s own pipeline as FXR0906 (ApoC3 siRNA), phase 2, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 27, 2026First study: phase 1 study in Healthy Adult VolunteersFirst studyNCT07766759 · 24 planned · China
  2. Oct 13, 2026Phase 2 study in DiseasePhase 2 reachedNCT07889245 · 192 planned · China

Ahead

  1. Sep 24, 2027Primary completion: phase 1 study in Healthy Adult VolunteersNCT07766759
  2. Aug 24, 2028Primary completion: phase 2 study in DiseaseNCT07889245

TargetBeta

“ApoC3 siRNA”the company's pipeline, read by Claude · source

Other programs on APOC3

ProgramCompanyFurthest phaseStudies
HRS-7249Jiangsu HengRui Medicinephase 24
CS-121rulecorrectsequence-therapeutics-co-ltdearly phase 12

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07889245Disease · China2Not yet recruitingAug 24, 2028192
NCT07766759Healthy Adult Volunteers · China1Not yet recruitingSep 24, 202724

How it is read

Names in the registry

  • “FXR0906 injection”, 3 entries
  • “Intervention1: FXR0906 injection”, 1 entry
  • “Intervention2: FXR0906 injection”, 1 entry

Codes read as this program: FXR0906.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.